PCN58 Estimation of Post-Infusion Costs of Care for Patients With Relapsed and Refractory Multiple Myeloma (RRMM) Who Received Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.150
https://www.valueinhealthjournal.com/article/S1098-3015(21)00367-3/fulltext
Title :
PCN58 Estimation of Post-Infusion Costs of Care for Patients With Relapsed and Refractory Multiple Myeloma (RRMM) Who Received Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00367-3&doi=10.1016/j.jval.2021.04.150
First page :
Section Title :
Open access? :
No
Section Order :
10727